Switglim ms
Each uncoated bilayered tablet contains: glimepiride + metformin + sitagliptin
1 x 15 tab/ strip
Switglim ms is a triple oral antidiabetic therapy designed for comprehensive glycemic control in patients with type 2 diabetes mellitus: glimepiride (a sulfonylurea) stimulates insulin secretion from pancreatic β-cells by acting on atp-sensitive potassium channels, enhancing postprandial glucose control. 🔹 metformin (sustained release) reduces hepatic gluconeogenesis, decreases intestinal glucose absorption, and improves peripheral insulin sensitivity, promoting long-term glycemic stability. 🔹 sitagliptin (a dpp-4 inhibitor) increases active incretin levels (glp-1 and gip), enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner.
As prescribed by physician/ respective specialist or rmp
For adequate glycemic control in t2dm
Mild and transient; may include: • hypoglycaemia • nausea / diarrhoea • abdominal discomfort • headache
Triple-targeted mechanism for superior glycemic control:
glimepiride: increases pancreatic insulin release.
Metformin: decreases hepatic glucose output and improves insulin sensitivity.
Sitagliptin: enhances incretin action to balance insulin and glucagon.
This synergy reduces hba1c effectively and maintains fasting and postprandial glucose levels.
No
